CAH at a glance
Cardinal Health (CAH, SEC CIK 721371) filed its latest 10-K annual report on August 11, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on October 1, 2026 and Form 4 insider filings as recently as August 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Cardinal Health (CAH) reported revenue of $254.2 billion (up 14.2% from FY2025) and net income of $1.7 billion. Diluted EPS was $7.23.
- As of June 30, 2026, 50 institutional investment managers tracked by SignalX reported holding Cardinal Health (CAH) shares worth $24.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Hollar Jason M. on August 19, 2026 of 6,244 shares at $237.88 per share.
- In the last 90 days, CAH insiders reported 0 open-market purchases ($0) and 31 open-market sales ($59.6M) on Form 4, a net sale of $59.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $254.2B
- +14.2% vs prior year
- Insiders · 90 days
- 0 buys · 31 sells
- Net −$59.6M
- 13F holders
- 50 funds
- $24.4B · +3 vs prior quarter
- Latest 8-K
- Oct 1, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $254.2B, up 14% YoY; Pharma segment up 15% to $234.8B, GMPD flat at $12.7B, Other +26% to $6.8B
- Operating margin approx. 1.03% ($2.613B / $254.2B) GAAP operating earnings up 15%, Non-GAAP margin 1.43% ($3.624B), Non-GAAP operating earnings up 30%
- Best segment: Pharma profit $2.783B up 23%; Worst: GMPD profit $258M up 91% but lowest dollar profit among segments
- Cash flow: Operating cash flow $5.2B; Capex $649M; Dividends $491M; Share repurchases $1.4B; Solaris Health acquisition $1.9B; New long-term debt net $1B; Cash and equivalents $4.9B
- Forward outlook: Management warns of tariff-related risks, regulatory uncertainties on branded pharma pricing, moderating GLP-1 demand, expects FY27 capex ~$700M, new $5B share repurchase program authorized
Business Overview
- Section 'business' was empty or not found.
Risk Factors
- DOJ Civil Investigative Demand November 2023 for potential Anti-Kickback Statute and False Claims Act violations in 2022 acquisition
- $200M IEEPA tariffs paid on GMPD segment goods with $200M receivable recorded in Q4 FY26 for expected U.S. Government refund
- FDA April 2024 warning letter on plastic syringes from Chinese manufacturer lacking 510(k) clearance, requiring corrective actions
- Competitive pressure from healthcare industry consolidation risking customer loss due to greater negotiating power of combined enterprises
- IRS tax audit challenging CARES Act self-insurance losses risking $400M additional tax expense plus $1.4B liability for 2015-2020 fiscal years
AI summary of the CAH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Risk Factors
- No risk-factor text provided; only filing index and signatures included
AI summary of the CAH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Binding letter of intent extends pharmaceutical distribution agreements with CVS Health through June 2032
- Long-duration CVS relationship provides visibility into Cardinal Health’s distribution revenue
Item 2.02: Results of Operations and Financial Condition
- Fiscal-year and quarterly results released for periods ended June 30, 2026
- Exhibit 99.1 contains Cardinal Health’s earnings figures and management commentary
Item 7.01: Regulation FD Disclosure
- Management webcast scheduled for August 11, 2026 at 8:30 a.m. Eastern
- Discussion covers quarter and fiscal year ended June 30, 2026
Item EX-99.1: Item EX-99.1
- Q4 revenue rose 6% to $63.7B, while non-GAAP EPS increased 40% to $2.91
- Underlying Q4 non-GAAP EPS rose 25% to $2.60 excluding the $0.31 IEEPA tariff refund benefit
Item 1.01: Entry into a Material Definitive Agreement
- Terminated facilities involved financial institutions with ongoing commercial and investment-banking relationships with Cardinal Health
- BOA and JPM affiliates remain commercial-paper dealers, preserving banking ties despite facility termination
Item 1.02: Termination of a Material Definitive Agreement
- Termination of $2.0B five-year revolving credit facility, reducing committed liquidity capacity
- Termination of $1.0B 364-day revolving facility, eliminating additional short-term borrowing availability
AI summaries of CAH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CAH
Don't miss the next CAH filing
- Alerts as it files. A push when CAH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CAH, by share count.
- Ask anything. An AI agent that reads every CAH filing and answers with sources.
CAH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hollar Jason M. | Sell | Aug 19, 2026 | 6,244 | $237.88 |
| Hollar Jason M. | Sell | Aug 19, 2026 | 6,731 | $236.46 |
| Hollar Jason M. | Sell | Aug 19, 2026 | 5,704 | $235.34 |
| Hollar Jason M. | Sell | Aug 19, 2026 | 16,187 | $237.23 |
| Scherer Mary C. | Sell | Aug 19, 2026 | 100 | $237.40 |
| Scherer Mary C. | Sell | Aug 19, 2026 | 2,202 | $237.39 |
| Hollar Jason M. | Sell | Aug 19, 2026 | 6,206 | $233.22 |
| Hollar Jason M. | Sell | Aug 19, 2026 | 3,457 | $234.29 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $222.6B | $254.2B |
| Gross Profit | - | $8.2B | $9.8B |
| Operating Income | - | $2.3B | $2.6B |
| Net Income | - | $1.6B | $1.7B |
| Gross Margin | - | 3.7% | 3.8% |
| Op. Margin | - | 1.0% | 1.0% |
| Net Margin | - | 0.7% | 0.7% |
| Balance Sheet | |||
| Total Assets | $45.1B | $53.1B | $57.3B |
| Equity | - | -$2.8B | -$2.9B |
| ROE | - | -56.1% | -59.5% |
| Per Share | |||
| EPS | - | $6.45 | $7.23 |
| Cash Flow | |||
| Operating CF | - | $2.4B | $5.2B |
| CapEx | $511.0M | $547.0M | $649.0M |
Source: XBRL data in Cardinal Health (CAH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CAH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 50 | $24.45B |
| Q1 2026 | 47 | $22.85B |
| Q4 2025 | 47 | $22.71B |
| Q3 2025 | 49 | $18.67B |
| Q2 2025 | 46 | $19.43B |
| Q1 2025 | 42 | $11.64B |
| Q4 2024 | 39 | $8.96B |
| Q3 2024 | 35 | $4.22B |
- Invesco Ltd+1.23M (+35%)
- T. Rowe Price Group+373.4K (+20%)
- JPMorgan Chase & Co+352.1K (+15%)
- Renaissance Technologies LLC+205.3K (+60%)
- Wells Fargo & Co+202.2K (+28%)
- FMR LLC (Fidelity)−2.18M (-51%)
- Citadel Advisors LLC−2.14M (-92%)
- BlackRock−2.00M (-7%)
- Two Sigma Investments−438.5K (-100%)
- Millennium Management−424.9K (-63%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 355 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CAH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-K | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
Related Health Care companies
- COR · CencoraWholesale-Drugs, Proprietaries & Druggists' Sundries
- HLF · HERBALIFE LTD.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- MCK · McKesson CorporationWholesale-Drugs, Proprietaries & Druggists' Sundries
- NUS · NU SKIN ENTERPRISES, INC.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
CAH SEC filings: frequently asked questions
Are CAH insiders buying or selling?
In the last 90 days, Cardinal Health (CAH) officers, directors and 10% owners reported no open-market purchases and 31 open-market sales worth $59.6 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CAH stock?
As of June 30, 2026, the largest Cardinal Health (CAH) holders among the 13F filers tracked by SignalX were BlackRock ($6.3 billion), Vanguard Capital Management LLC ($3.6 billion), Vanguard Portfolio Management LLC ($3.3 billion), State Street Corp ($2.8 billion), Invesco Ltd ($1.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CAH's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Cardinal Health (CAH) reported revenue of $254.2 billion (up 14.2% from FY2025) and net income of $1.7 billion. Diluted EPS was $7.23. The figures come from the XBRL data in the 10-K.
What are the main risks in CAH's latest 10-K?
In the 10-K filed August 11, 2026, Cardinal Health (CAH) flagged: DOJ Civil Investigative Demand November 2023 for potential Anti-Kickback Statute and False Claims Act violations in 2022 acquisition. $200M IEEPA tariffs paid on GMPD segment goods with $200M receivable recorded in Q4 FY26 for expected U.S. Government refund. (AI summary of the Risk Factors section.)
What did CAH report in its latest 8-K?
Cardinal Health (CAH) filed an 8-K on October 1, 2026 reporting Item 7.01 (Regulation FD Disclosure). Binding letter of intent extends pharmaceutical distribution agreements with CVS Health through June 2032.
What are the latest CAH SEC filings?
Cardinal Health (CAH) filed its latest 10-K annual report on August 11, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on October 1, 2026 and a Form 4 insider filing on August 20, 2026.
What is CAH's SEC CIK number?
Cardinal Health (CAH)'s SEC Central Index Key (CIK) is 721371. EDGAR lists every CAH filing under that number.
Ask anything about CAH
The research agent reads CAH's filings, financials, insider trades and 13F holders, then answers with sources.